Contrast enhanced ultrasound in the detection of liver metastases: a prospective multi-centre dose testing study using a perfluorobutane microbubble contrast agent (NC100100)

Corréas, Jean-Michel; Low, Gavin; Needleman, Laurence; Robbin, Michelle L.; Cosgrove, David O.; Sidhu, Paul S.; Harvey, Chris J.; Albrecht, Thomas; Jakobsen, Jarl Å.; Brabrand, Knut; Jenett, M.; Bates, Jane; Claudon, M.; Leen, Edward

doi:10.1007/s00330-011-2114-6

Cited by 38 publications

(26 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They mainly arise from cancers in the gastrointestinal tract, pancreas, breast, and lung. CEUS has markedly improved the detection rate of liver metastases, with reported sensitivity and specificity ranging from 80% to 95% [85][86][87].…”

Section: Metastasesmentioning

confidence: 99%

Contrast-Enhanced Ultrasound of Focal Liver Lesions

D’Onofrio

Crosara

Robertis

et al. 2015

American Journal of Roentgenology

192

168

View full text Add to dashboard Cite

Focal liver lesions are usually detected incidentally during abdominal ultrasound. The injection of microbubble ultrasound contrast agents improves the characterization of focal liver lesions that are indeterminate on conventional ultrasound. The use of CEUS is recommended in official guidelines and suggested as a second diagnostic step after ultrasound detection of indeterminate focal liver lesions to immediately establish the diagnosis, especially for benign liver lesions, such as hemangiomas, avoiding further and more expensive examinations.

show abstract

Section: Metastasesmentioning

confidence: 99%

Contrast-Enhanced Ultrasound of Focal Liver Lesions

D’Onofrio

Crosara

Robertis

et al. 2015

American Journal of Roentgenology

192

168

View full text Add to dashboard Cite

show abstract

“…

Dear Editor, We thank Dr Frauscher for his careful appraisal of our recent study [1]. We are delighted that there are positive remarks.

…”

mentioning

confidence: 89%

Reply to letter to the editor re: contrast enhanced ultrasound in the detection of liver metastases: a prospective multi-centre dose testing study using a perfluorobutane microbubble contrast agent (NC100100)

et al. 2011

Self Cite

View full text Add to dashboard Cite

Dear Editor, We thank Dr Frauscher for his careful appraisal of our recent study [1]. We are delighted that there are positive remarks. However there are several aspects of the commentary we disagree with.The Edey et al. study [2] is misquoted. This study was an extension of a phase II multicentre trial (i.e. the current study) performed at a single site. It was therefore not the first study but a reported sub-series of patients (investigated with agent detection imaging, ADI)-an extension to the original large trial for which we are reporting. Edey et al. reported artefact only with the high doses with ADI and no other imaging technique. The primary aim of the paper was to see if ADI worked in the late phase following all the scheduled imaging as per protocol and to ascertain whether there was sufficient Sonazoid left around to perform ADI. Therefore there was no artefact described in our study with the low and high MI techniques, and this was not a secondary investigation within the definition of the protocol.Secondly, the Bernatik T et al. study [3] was of 1,349 patients, not 1,349 lesions. Our study was a detection study of lesions in the late phase while the Bernatik study was a characterization study of lesions during the complete vascular phase (arterial, portal and late). We have no doubt that were Sonazoid used for characterization, there would be improved diagnostic performance, and we agree that use of late phase imaging alone may influence accuracy of CEUS for liver imaging. Please note, however, that our results are relatively modest (78% sensitivity and 70% accuracy for 0.12 μL/kg dose group) in part because our per lesion analysis incorporated a relatively rigorous standard of reference (SOR) including the use of off-site reviewers. Incorrect lesion assignment to Couinard segments may also have led some true-positive lesions on US or CEUS being erroneously labelled as false positive on the SOR.We suggest that this dose-finding study, coupled with the very rigorous off-site blinded assessment, demonstrates the very robust nature of this technique using a versatile microbubble agent.The letter to which this is the reply can be found at http://dx.doi.

show abstract

“…Dear Editor, The study reported by Correas et al was designed to determine the optimal dose of NC100100 (Sonazoid®; Daiichi-Sankyo, Tokyo, Japan; GE Healthcare, Oslo, Norway) for detecting liver metastases in the late hepatospecific phase by a multi-centre approach [1]. Contrast-enhanced ultrasound (CEUS) produced a significant improvement compared to conventional ultrasound (US) in the sensitivity of lesion detection for each dose group (p<0.05) and for all doses combined (p<0.0001).…”

mentioning

confidence: 98%

Letter to the editor re: contrast enhanced ultrasound in the detection of liver metastases: a prospective multi-centre dose testing study using a perfluorobutane microbubble contrast agent (NC100100)

Frauscher

2011

Eur Radiol

View full text Add to dashboard Cite

Contrast enhanced ultrasound in the detection of liver metastases: a prospective multi-centre dose testing study using a perfluorobutane microbubble contrast agent (NC100100)

Abstract: The diagnostic performance of CEUS is dose dependent with the 0.12 μL/kg NC100100 dose group showing the greatest sensitivity and accuracy in detection of liver metastases.

Cited by 38 publications

References 13 publications

Contrast-Enhanced Ultrasound of Focal Liver Lesions

Contrast-Enhanced Ultrasound of Focal Liver Lesions

Reply to letter to the editor re: contrast enhanced ultrasound in the detection of liver metastases: a prospective multi-centre dose testing study using a perfluorobutane microbubble contrast agent (NC100100)

Letter to the editor re: contrast enhanced ultrasound in the detection of liver metastases: a prospective multi-centre dose testing study using a perfluorobutane microbubble contrast agent (NC100100)

Contact Info

Product

Resources

About